Herceptin founder snags $158M for his UCLA-biotech partnership TORL BioTherapeutics

Kyle LaHucik

Senior Reporter

One of the key researchers behind identifying HER2 as a breast cancer target — and turning that discovery into what became the blockbuster Herceptin — has formed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Herceptin founder snags $158M for his UCLA-biotech partnership TORL BioTherapeutics

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

At least seven drugmakers say they will participate in round two of IRA negotiations

Trump’s science crackdown hits rare disease research: ‘We need to sit down with Elon Musk’

Exclusive: Infectious disease doctors consider 'mini-ACIP' if RFK erodes CDC vaccine panel

Bipartisan 'pill penalty' fix and other bills vie for inclusion in reconciliation package

Lilly joins molecular glue field with Magnet deal worth up to $1.25B

How AI can address ongoing challenges in the life sciences industry

Her­ceptin founder snags $158M for his UCLA-biotech part­ner­ship TORL Bio­Ther­a­peu­tics

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Herceptin founder snags $158M for his UCLA-biotech partnership TORL BioTherapeutics